Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ra Pharmaceuticals, Inc. (NASDAQ: RARX).

Full DD Report for RARX

You must become a subscriber to view this report.


Recent News from (NASDAQ: RARX)

Ra Pharma completes End-of-Phase 2 interactions with FDA and design of Phase 3 PNH program
Ra Pharmaceuticals (NASDAQ: RARX ) completes End-of-Phase 2 interactions with the FDA for its global Phase 3 program of RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). More news on: Ra Pharmaceuticals, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 05 2018 09:25
Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
Plans to initiate a global, pivotal, single-arm Phase 3 trial in treatment-naïve PNH patients Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for its global Phase 3 program o...
Source: Business Wire
Date: September, 05 2018 07:30
Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group - Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RA PHARMCTL INC (NASDAQ:RARX), Oclaro, Inc. (NASDAQ:OCLR), Emergent Bioso...
Source: GlobeNewswire
Date: August, 15 2018 08:25
Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program
Surpassed target enrollment in Phase 2 trial of RA101495 SC for gMG Top-line data now expected around year-end 2018 Regulatory progress on Phase 3 PNH program Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the second quarter ended June 30, 2018 ...
Source: Business Wire
Date: August, 08 2018 07:15
Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?
I’ve been following Ra Pharmaceuticals ( RARX ) to some extent over the last few years due to my interest in rare diseases and the complement space. After discussing the company and its approach with one of our valued Growth Stock Forum members in the chat room, I decided to take a de...
Source: SeekingAlpha
Date: July, 30 2018 19:43
Riding Ra Pharmaceuticals
Shares of Ra Pharmaceuticals (NASDAQ: RARX ) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. With an 86% gain in RARX,...
Source: SeekingAlpha
Date: July, 23 2018 06:12
Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt
Welcome to Achillion ( ACHN ) - I've been following the company for a bit, but only after the JNJ Hep C disaster, so I won't be painting much of a picture for that asset, nor times before it. Rather I want to focus on lead asset 4471 and their second-generation drugs. And the ridiculous amount...
Source: SeekingAlpha
Date: July, 09 2018 12:45
Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the presentation of scientific data at the 23 rd Congress of the European Hematology Association (EHA), June 14-17, 2018 in Stockholm, Sweden. “The characterization of our first-in-class, orally bioavailable, small molecules ...
Source: Business Wire
Date: June, 15 2018 07:00
Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology
- Phase 2 Trial in Generalized Myasthenia Gravis Over 50% Enrolled Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the design of its Phase 2 clinical trial of RA101495 SC for the treatment of generalized myasthenia gravis (gMG) will be presented at the 4 th Congress of th...
Source: Business Wire
Date: June, 05 2018 07:00
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXN’s competition. I have previously reviewed a large number of ALXN’s compet...
Source: SeekingAlpha
Date: May, 31 2018 09:04

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0812.0912.2512.4911.8487248,529
2018-05-176.366.276.466.21102,610

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0719,81089,30422.1827Cover
2018-12-0613,09998,12913.3488Cover
2018-12-0424,68782,64029.8729Cover
2018-12-0368,796169,41840.6073Short
2018-11-3041,78996,47543.3159Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RARX.


About Ra Pharmaceuticals, Inc. (NASDAQ: RARX)

Logo for Ra Pharmaceuticals, Inc. (NASDAQ: RARX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $202,114,642 - 05/11/2018
  • Issue and Outstanding: 32,286,684 - 03/02/2018

 


Recent Filings from (NASDAQ: RARX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 09 2018
Information for Proxy Statement under Rule 14a-101
Filing Type: DEFR14AFiling Source: edgar
Filing Date: May, 07 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 02 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 27 2018

 

 


Daily Technical Chart for (NASDAQ: RARX)

Daily Technical Chart for (NASDAQ: RARX)


Stay tuned for daily updates and more on (NASDAQ: RARX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RARX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RARX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RARX and does not buy, sell, or trade any shares of RARX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/